NEOGENOMICS INC
No enriched coverage for $NEO in the last 7 days.
No SEC Form 4 filings for $NEO in the last 30 days.
NeoGenomics, Inc. (NEO) reported its Q1 adjusted EPS at $0.01 per share, matching FactSet's estimate. The company also announced full-year 2026 revenue expectations of $797 million to $803 million, slightly above FactSet's estimate of $796.7 million. These results were published on April 28, 2026.
Tudor Investment Corp ET AL significantly reduced its stake in NeoGenomics, Inc. by selling 320,361 shares, bringing its total holdings to 375,351 shares valued at approximately $2.9 million. The medical research company recently reported stronger-than-expected quarterly earnings, beating analyst estimates for both EPS and revenue. Despite this, the stock saw a recent decline, opening down 7.3% at $7.19, and holds a consensus analyst rating of "Hold" with a target price of $11.86.
This article is incomplete and contains no meaningful content. Therefore, a summary cannot be provided.
